Inhibitors of kinases
The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
1. A compound having the formula
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
3. A method for treating a VEGFR-2 and/or FGFR-1 related cancer in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound having the formula
or a pharmaceutically acceptable salt thereof, wherein the cancer is hepatocellular cancer, colorectal cancer or non-small cell lung cancer.
4. A method for treating a VEGFR-2 and/or FGFR-1 related cancer in a mammal in need thereof comprising treating said mammal with a therapeutically effective amount of a compound having the formula
or a pharmaceutically acceptable salt thereof, wherein the cancer is hepatocellular cancer, colorectal cancer or non-small cell lung cancer.